SciELO - Scientific Electronic Library Online

 
vol.33 número1¿Ha mejorado la supervivencia del injerto tras el trasplante renal en la era de la moderna inmunosupresión?Características del metabolismo óseo y mineral en pacientes con enfermedad renal crónica en estadios 3-5 no en diálisis: resultados del estudio OSERCE índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google

Compartilhar


Nefrología (Madrid)

versão On-line ISSN 1989-2284versão impressa ISSN 0211-6995

Resumo

CAMPISTOL, Josep M. et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment: A consensus document. Nefrología (Madr.) [online]. 2013, vol.33, n.1, pp.27-45. ISSN 1989-2284.  https://dx.doi.org/10.3265/Nefrologia.pre2012.Nov.11781.

Haemolytic uraemic syndrome (HUS) is a clinical entity defined as the triad of nonimmune haemolytic anaemia, thrombocytopenia, and acute renal failure, in which the underlying lesions are mediated by systemic thrombotic microangiopathy (TMA). Atypical HUS (aHUS) is a sub-type of HUS in which the TMA phenomena are the consequence of decreased regulation of the alternative complement pathway on cell surfaces due to a genetic cause. aHUS is an extremely rare disease that, despite the administration of standard treatment with plasma therapy, often progresses to terminal chronic renal failure with a high associated rate of mortality. In recent years, research has established the key role that the complement system plays in the induction of endothelial damage in patients with aHUS, through the characterisation of multiple mutations and polymorphisms in the genes that code for certain complement factors. Eculizumab is a monoclonal antibody that inhibits the terminal fraction of the complement protein, blocking the formation of a cell membrane attack complex. In prospective studies in patients with aHUS, administering eculizumab produces a rapid and sustained interruption in the TMA process, with significant improvements in long-term renal function and an important decrease in the need for dialysis or plasma therapy. In this document, we review and bring up to date the important aspects of this disease, with special emphasis on how recent advancements in diagnostic and therapeutic processes can modify the treatment of patients with aHUS.

Palavras-chave : Atypical haemolytic uraemic syndrome; Eculizumab; Complement; Thrombotic microangiopathy.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )

 

Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons